CSIMarket
 


Repligen Corp  (RGEN)
Other Ticker:  
 

Repligen's Leverage Ratio

RGEN's quarterly Leverage Ratio and Total Liabilities, Equity growth


Due to repayements of liabilities of -9.2% Repligen improved Leverage Ratio in third quarter 2023 to 0.26, below the company's average Leverage Ratio.

Within Biotechnology & Pharmaceuticals industry in the third quarter 2023, 22 other companies have achieved lower Leverage Ratio than Repligen in the III Quarter 2023. While Leverage Ratio total ranking has improved so far in the third quarter 2023 to 216, from total ranking in the second quarter 2023 at 413 .

Explain Leverage Ratio?
Who are RGEN Customers?
What are RGEN´s Total Liabilities?


RGEN Leverage Ratio (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Equity Change 8.36 % 9.17 % 9.86 % 9.18 % 6.99 %
Y / Y Total Liabilities Change -14.98 % -8.39 % -2.92 % 1.17 % 17.99 %
Leverage Ratio MRQ 0.26 0.29 0.3 0.32 0.33
RGEN's Total Ranking # 216 # 413 # 705 # 328 # 823
Seq. Equity Change 0.89 % 1.57 % 1.56 % 4.12 % 1.65 %
Seq. Total Liabilities Change -9.2 % -2.47 % -2.84 % -1.18 % -2.16 %



Leverage Ratio third quarter 2023 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 23
Healthcare Sector # 105
Overall Market # 216


Leverage Ratio Statistics
High Average Low
0.72 0.28 0.1
(Jun 30 2016)   (Mar 31 2014)




Financial Statements
Repligen's Equity $ 1,989 Millions Visit RGEN's Balance sheet
Repligen's Total Liabilities $ 522 Millions Visit RGEN's Balance sheet
Source of RGEN's Sales Visit RGEN's Sales by Geography


Cumulative Repligen's Leverage Ratio

RGEN's Leverage Ratio for the trailling 12 Months

RGEN Leverage Ratio

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Equity TTM Growth 8.36 % 9.17 % 9.86 % 9.18 % 6.99 %
Y / Y Total Liabilities TTM Growth -14.98 % -8.39 % -2.92 % 1.17 % 17.99 %
Leverage Ratio TTM 0.29 0.31 0.33 0.34 0.34
Total Ranking TTM # 528 # 618 # 38 # 534 # 811
Seq. Equity TTM Growth 0.89 % 1.57 % 1.56 % 4.12 % 1.65 %
Seq. Total Liabilities TTM Growth -9.2 % -2.47 % -2.84 % -1.18 % -2.16 %


On the trailing twelve months basis Due to repayements of liabilities of -9.2% Repligen decreased Leverage Ratio in the 12 months ending in III Quarter 2023 to 0.29, below the company's average Leverage Ratio.
Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Biotechnology & Pharmaceuticals industry 48, during the past 12 months, other companies have achieved lower Leverage Ratio than Repligen. While Leverage Ratio total ranking has improved so far to 528, from total ranking in previous 12 month period at 618.

Explain Leverage Ratio?
Who are RGEN Customers?
What are RGEN´s Total Liabilities?

TTM Leverage Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 49
Healthcare Sector # 276
Within the Market # 528


trailing twelve months Leverage Ratio Statistics
High Average Low
0.7 0.3 0.12
(Mar 31 2017)   (June 30. 2014)




Companies with similar Leverage Ratio in the quarter ending Sep 30 2023, within Biotechnology & Pharmaceuticals Industry Leverage RatioSep 30 2023 MRQ Total LiabilitiesSep 30 2023 MRQ Equity
Bluebird Bio Inc   0.71 $ 159.049  Millions$ 222.536  Millions
Xtant Medical Holdings Inc   0.68 $ 37.322  Millions$ 54.681  Millions
Beam Therapeutics Inc   0.66 $ 511.593  Millions$ 778.941  Millions
Sangamo Therapeutics Inc   0.63 $ 84.775  Millions$ 134.922  Millions
Ginkgo Bioworks Holdings Inc   0.62 $ 773.709  Millions$ 1,252.683  Millions
Zura Bio Limited  0.62 $ 39.837  Millions$ 64.755  Millions
Elevation Oncology inc   0.60 $ 37.559  Millions$ 62.416  Millions
Senti Biosciences Inc   0.59 $ 48.830  Millions$ 82.936  Millions
Inmune Bio Inc   0.57 $ 25.155  Millions$ 43.933  Millions
Lineage Cell Therapeutics Inc   0.57 $ 38.036  Millions$ 66.660  Millions
Aligos Therapeutics Inc   0.57 $ 31.031  Millions$ 54.821  Millions
Vericel Corporation  0.56 $ 113.745  Millions$ 204.380  Millions
C4 Therapeutics Inc   0.54 $ 116.989  Millions$ 216.024  Millions
Miromatrix Medical inc   0.51 $ 7.879  Millions$ 15.542  Millions
Vaxart Inc   0.48 $ 34.121  Millions$ 71.521  Millions
Moderna Inc   0.45 $ 5,995.000  Millions$ 13,455.000  Millions
Qiagen N v   0.44 $ 1,692.857  Millions$ 3,807.764  Millions
Recursion Pharmaceuticals Inc   0.44 $ 192.858  Millions$ 437.967  Millions
Coeptis Therapeutics Holdings Inc   0.43 $ 2.134  Millions$ 5.012  Millions
Neurocrine Biosciences Inc   0.42 $ 846.100  Millions$ 2,002.100  Millions
Scholar Rock Holding Corp  0.41 $ 69.489  Millions$ 167.665  Millions
Instil Bio Inc   0.40 $ 94.426  Millions$ 234.024  Millions
Editas Medicine Inc   0.40 $ 144.188  Millions$ 360.462  Millions
Tscan Therapeutics Inc   0.39 $ 65.380  Millions$ 168.961  Millions
Ikena Oncology Inc   0.39 $ 59.991  Millions$ 155.344  Millions
Seagen Inc   0.37 $ 954.716  Millions$ 2,550.421  Millions
Monte Rosa Therapeutics Inc   0.37 $ 67.579  Millions$ 184.524  Millions
Sophia Genetics Sa  0.36 $ 54.714  Millions$ 151.442  Millions
Bioatla Inc   0.36 $ 34.006  Millions$ 94.703  Millions
Cognition Therapeutics inc   0.34 $ 9.846  Millions$ 28.926  Millions

Date modified: 2023-11-01T10:38:03+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com